Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Joshua C. Gray |
Documentos disponibles escritos por este autor (1)
Refinar búsquedaMDMA and MDMA- assisted therapy / Aaron S. Wolfgang en The American Journal of Psychiatry, Año 2025 - Vol. 182 - No.1 (Enero)
[artículo]
Título : MDMA and MDMA- assisted therapy Tipo de documento: texto impreso Autores: Aaron S. Wolfgang, Autor ; Gregory A. Fonzo, Autor ; Joshua C. Gray, Autor Fecha de publicación: 2025 Artículo en la página: pp. 79-103 Idioma : Inglés (eng) Idioma original : Inglés (eng) Etiquetas: Estudios clínicos de medicamentos, Trastornos depresivos, MDMA, Trastorno depresivo mayor, Trastorno de estrés postraumático (TEPT). Resumen: MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as “Ecstasy” or “Molly,” has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the initial New Drug Application in 2024. Link: ./index.php?lvl=notice_display&id=31560
in The American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 79-103[artículo] MDMA and MDMA- assisted therapy [texto impreso] / Aaron S. Wolfgang, Autor ; Gregory A. Fonzo, Autor ; Joshua C. Gray, Autor . - 2025 . - pp. 79-103.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 79-103
Etiquetas: Estudios clínicos de medicamentos, Trastornos depresivos, MDMA, Trastorno depresivo mayor, Trastorno de estrés postraumático (TEPT). Resumen: MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as “Ecstasy” or “Molly,” has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the initial New Drug Application in 2024. Link: ./index.php?lvl=notice_display&id=31560
